RTW

Reliance Matrix introduces Text Back technology to its event-driven, omni-channel claim management experience

Retrieved on: 
Wednesday, April 19, 2023
Legal, Technology, Insurance, Human Resources, Finance, Other Technology, Professional Services, Business, Data Management, Other Professional Services, Workforce, HR, Matrix, Calendar, HCM, Human resource management, RTW, Online shopping

Reliance Matrix, a leading provider of employee benefits solutions and technology enabled absence and productivity services, has launched new “Text Back” technology into its integrated claim experience across all solutions and services.

Key Points: 
  • Reliance Matrix, a leading provider of employee benefits solutions and technology enabled absence and productivity services, has launched new “Text Back” technology into its integrated claim experience across all solutions and services.
  • This latest innovation allows employees to easily confirm or change their return-to-work status through text messaging, enhancing the employee experience and rapidly updating employee information across proprietary Matrix platforms as well as client HCM systems.
  • As a best practice, Reliance Matrix absence management specialists proactively reach out 5 days prior to the employee’s scheduled return to confirm the date and other important information.
  • “Our clients confirm Text Back is a quantum leap forward in service and accuracy” said Mark Marsters, President of Matrix Absence Management and Chief Operating Officer of Reliance Matrix.

Lost Money in Cutera, Inc.?

Retrieved on: 
Thursday, April 13, 2023
Class Action Lawsuit, Professional Services, Legal, Investment, Plant, Eric Gibbs, RTW, Mowry, Annual report, LP, News, Private investigator, Management

Gibbs Law Group is investigating a potential Cutera Securities Class Action Lawsuit on behalf of investors who lost money in Cutera, Inc.

Key Points: 
  • Gibbs Law Group is investigating a potential Cutera Securities Class Action Lawsuit on behalf of investors who lost money in Cutera, Inc.
    To speak with an attorney regarding this class action lawsuit investigation, click here or call (888) 410-2925.
  • Cutera announced on February 28, 2023, that it would fail to file its 2022 annual report in a timely manner.
  • Following news of the boardroom personnel changes, Cutera’s stock price plummeted 28% on April 12, 2023, causing significant harm to investors.
  • Our investigation concerns whether Cutera has violated federal securities laws by providing false or misleading statements to investors.

Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 30, 2023
Patent, REMS, FDA Adverse Event Reporting System, United States Court of Appeals for the Federal Circuit, Cataplexy, American Neurological Association, Marketing, EDS, Narcolepsy, Federal district, Orange Book, District court, ANA, Patient, United States courts of appeals, Risk, RTW, American College of Chest Physicians, Webcast, Jazz Pharmaceuticals, Growth, American College, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Douglas v. U.S. District Court ex rel Talk America, Food, Generic drug, Pharmaceutical industry, Cryptocurrency, Music, Avadel Pharmaceuticals, FAERS

ET

Key Points: 
  • ET
    DUBLIN, Ireland, March 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and announced its financial results for the fourth quarter ended December 31, 2022.
  • Collectively, these milestones move us closer to the potential commercialization of LUMRYZ,” said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals.
  • I want to thank all stakeholders including patients, healthcare practitioners, and our investors for their strong support during this process.
  • Avadel will host a conference all and live audio webcast to discuss its fourth quarter and full year quarter 2022 financial results and provide a corporate update today at 8:30 a.m.

Avadel Pharmaceuticals Enters into Royalty Agreement with RTW Investments for up to $75 Million

Retrieved on: 
Wednesday, March 29, 2023
Cataplexy, Investment, EDS, Narcolepsy, BofA Securities, Exchange, Gibson, Jefferies Group, MD, RTW, LP, Pharmaceutical industry, Avadel Pharmaceuticals

DUBLIN, Ireland, March 29, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its entry into a royalty agreement with RTW Investments, LP and certain of its affiliates (“RTW”) for up to $75 million to support the potential commercialization of LUMRYZ™ for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Concurrently, the company extended the maturity of $96.2 million of its convertible notes to 2027.

Key Points: 
  • Concurrently, the company extended the maturity of $96.2 million of its convertible notes to 2027.
  • Further, we are pleased to have the continued support of RTW Investments, a premier partner known for its strategic investments in promising healthcare companies and assets,” said Greg Divis, Chief Executive Offer at Avadel Pharmaceuticals.
  • Following the closing of the Exchange, approximately $21.2 million in existing notes will remain outstanding with terms unchanged.
  • BofA Securities acted as sole structuring agent for Avadel on the royalty agreement transaction.

USW Welcomes Repeal of Michigan's Anti-Worker RTW Laws

Retrieved on: 
Wednesday, March 22, 2023
Senate, Metal, Democrat, USW, Table tennis rubber, Woman, Human, Multimedia, Public sector, United Steelworkers, Risk, Mining, Paper, House, Glass, Safety, Nursing, RTW

"Corporations and Republicans rammed RTW through the legislature in 2012 to bust unions and silence workers," he added.

Key Points: 
  • "Corporations and Republicans rammed RTW through the legislature in 2012 to bust unions and silence workers," he added.
  • States with RTW laws allow workers to receive union services for free.
  • "It's all about dividing and conquering," observed Kent Holsing, president of USW Local 12075 in Midland, Mich., one of thousands of union members who turned out for rallies demanding the repeal of RTW.
  • Workers in RTW states make significantly lower wages —and they're less likely to have employer-provided health insurance—than their counterparts elsewhere.

RTW Charitable Foundation Supports Medical Relief Efforts in Turkey and Syria with $50,000 Emergency Response Grant to the Syrian American Medical Society (SAMS) Foundation

Retrieved on: 
Tuesday, March 21, 2023
General Health, Professional Services, Philanthropy, Mental Health, Asset Management, Hospitals, Fund Raising, Foundation, Nursing, Finance, Other Philanthropy, Health, SAMS, Partnership, Depression, Tourniquet, Anxiety, Nonprofit organization, Syrian American Medical Society, Stress-related disorders, National Association Medical Staff Services, Triage, Patient, Earthquake, Child, RTW, Community engagement, Johns Hopkins, Trauma, Bandage, Mental health, Razom, Counselor, Safety, Element, Substance abuse, Pharmaceutical industry

RTW Charitable Foundation today announced a $50,000 donation to the Syrian American Medical Society (“SAMS”) Foundation, a global medical relief organization working on the front lines of crisis relief in Syria and beyond to save lives and alleviate suffering, to provide emergency relief to victims of the 7.8 magnitude earthquake that struck Southern Turkey along the border of Syria on February 6.

Key Points: 
  • RTW Charitable Foundation today announced a $50,000 donation to the Syrian American Medical Society (“SAMS”) Foundation, a global medical relief organization working on the front lines of crisis relief in Syria and beyond to save lives and alleviate suffering, to provide emergency relief to victims of the 7.8 magnitude earthquake that struck Southern Turkey along the border of Syria on February 6.
  • RTW Charitable Foundation’s mission is to power rare disease research, medical innovation, and humanitarian collaborations to improve the health of underserved communities.
  • “The devastation we’re seeing in Turkey and Syria goes beyond the destruction of infrastructure and even the physical injuries suffered by its victims.
  • The grant funded the distribution of 1,400 tactical medical backpacks with about 38,000 bandages, tourniquets, and wound dressings.

UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments

Retrieved on: 
Thursday, March 16, 2023
Research, General Health, Pharmaceutical, Oncology, Public Relations, Investor Relations, Clinical Trials, Science, Biotechnology, Communications, FDA, Other Science, Health, Investment, Conference, RTW, Webcast, Urology, Bladder cancer, Software, Financial result, Patient, Mitomycins, Quarter, Stenosis, SUO, Growth, LIBOR, Tax, Safety, ATLAS, NDA, OLYMPUS, DOR, Neoplasm, Recurrence, Pharmaceutical industry, Nursing, Video game, Cryptocurrency, Bank, Broadcasting

Supported by a growing body of real-world outcomes data, we delivered our strongest ever JELMYTO net sales in Q4 helping propel ~34% full-year growth for fiscal 2022.

Key Points: 
  • Supported by a growing body of real-world outcomes data, we delivered our strongest ever JELMYTO net sales in Q4 helping propel ~34% full-year growth for fiscal 2022.
  • Fourth Quarter and Full Year 2022 Financial Results:
    JELMYTO Revenue: UroGen reported JELMYTO net product revenues for the fourth quarter 2022 of $18.1 million, compared to $16.2 million for the same period in 2021.
  • Research and development expenses for the full year 2022 were $52.9 million, including non-cash share-based compensation expense of $2.6 million.
  • SG&A Expense: Selling, general and administrative expenses for the fourth quarter 2022 were $21.6 million, including non-cash share-based compensation expense of $1.8 million.

CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies

Retrieved on: 
Wednesday, March 1, 2023
Janus, B-ALL, Disease resistance, JD, Transplant, Therapy, Safety, Doctor of Philosophy, Cancer, MD, Survival, Leukapheresis, Crystal Mackall, Breakthrough therapy, CD19, Disease, CAR, Engineering, Nex Entertainment, B-cell lymphoma, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cellular, ORR, T. Rowe Price, CD22, Third Rock Ventures, LP, Canadian Aviation Regulations, Emerson Collective, Investment, Wellington Management Company, CR, RTW, Food, Financial services, Pharmaceutical industry, Vaccine, Blood

SAN MATEO, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced the close of a $200 million oversubscribed and upsized Series A financing. The financing was co-led by Third Rock Ventures, RTW Investments, LP and Perceptive Xontogeny Venture Fund, and includes additional new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management, funds and accounts advised by T. Rowe Price Associates, Inc., Cormorant Asset Management and Piper Heartland. Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing. CARGO is advancing what will potentially be a first and best-in-class autologous CD22 chimeric antigen receptor T-cell (CAR T) therapy as well as a pipeline of next generation CAR T-cell therapies for cancer using its proprietary cell engineering platform technologies.

Key Points: 
  • Founding investor Samsara BioCapital and existing seed investors Red Tree Venture Capital and Emerson Collective also participated in the financing.
  • CARGO also intends to advance its proprietary platform technologies and discovery-stage programs to deliver better outcomes for patients with cancer who have high unmet need.
  • CARGO Therapeutics is building upon deep expertise in understanding resistance to CAR T-cell therapies to deliver next generation cell products for patients,” said Gina Chapman, CEO of CARGO Therapeutics.
  • The founders' overarching mission was to overcome CAR resistance to extend the clinical benefit of CARs for patients in need.

Intend™ Announces ePrescriptions and Automated Insurance Verification

Retrieved on: 
Thursday, February 16, 2023
Return, Insurance, Physician, Pharmacy, Intend, Patient, RTW, Health care, Pharmaceutical industry, MD

FULLERTON, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intend™, a patient-centric healthcare management software provider, announces support for ePrescriptions and automated insurance verification .

Key Points: 
  • FULLERTON, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intend™, a patient-centric healthcare management software provider, announces support for ePrescriptions and automated insurance verification .
  • "Our partners are very excited about these two significant enhancements to the Intend Platform," said Intend President Eric Kupferberg.
  • "This functionality is especially useful for providers that are expanding their service offerings to include additional medical services."
  • Knowing the insurance benefits are verified prior to the appointment is a huge time saver for both our staff and patients.

Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination With Compute Health Acquisition Corp.

Retrieved on: 
Thursday, February 9, 2023
Biotechnology, Technology, Professional Services, Health, General Health, Other Technology, Medical Devices, Surgery, Nanotechnology, Fitness & Nutrition, Finance, Slate, LLP, NYSE, Safety, Acquisition, Chef, Kirkland & Ellis, RTW, Political moderate, Overweight, Credit Suisse, Weight loss, PIPE, Sleep, Fortification, ESTA, Jefferies Group, Type 2 diabetes, LP, Entrepreneurship, Anesthesia, Prediabetes, Growth, IP, Mental health, MD, DNA, Life, Security (finance), Obesity, Patient, Fortress Investment Group, Harvard Medical School, Endoscopy, Fear, Diet, Intellectual property, Skadden, Arps, Slate, Meagher & Flom, Artificial intelligence, Form, Wardwell, A1C, Investment, Cryptocurrency, Medical device, Pharmaceutical industry, Financial services, Jefferies

While weight loss drugs have shown to be effective, they often need to be used for life at significant costs and can result in undesirable side effects.

Key Points: 
  • While weight loss drugs have shown to be effective, they often need to be used for life at significant costs and can result in undesirable side effects.
  • Both patients and providers are in need of clinically proven weight loss solutions that can scale globally and address these shortcomings.
  • “The global opportunity to reliably drive safe and effective weight loss taps both medical and aesthetic needs of consumers and has unlimited potential.
  • In connection with the proposed transaction, holders of Compute Health Class A common stock will have the right to redeem their Compute Health Class A shares.